Internship

Co-Op – Discovery Immunology

Spring 2025

Posted on 9/13/2024

Bristol-Myers Squibb

Bristol-Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Biotechnology
Healthcare

Princeton, NJ, USA

Role may require at least 50% onsite presence in Princeton, NJ.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • Completed 2+ years of a relevant life science undergraduate degree or be enrolled in a relevant graduate level degree program.
  • Prior relevant research experience including mammalian tissue culture required.
  • Experience in molecular techniques (RT-PCR, western blot, etc.) preferred.
  • A general practical or theoretical understanding of immunology is preferred.
  • Possess a high level of critical thinking, high energy, independence, a strong desire to learn new techniques, and the ability to work in a highly dynamic research organization.
  • Minimum three (3) semesters of laboratory course work.
  • Strong academic record (≥ 3.0 GPA).
  • Able to commit to continuous full-time employment from January-July/August.
  • Excellent oral, written, and presentation skills.
  • Must be willing to work with human and mouse primary tissues.
Responsibilities
  • Actively contribute to discovery project which is aligned with Immunology Research objectives and participate in BMS Co-op program requirements.
  • Isolation and culture of purified primary mammalian immune cells.
  • Design and perform genetic knockout experiments in primary immune cells using an established CRISPR/Cas9 gene knockout system.
  • Assess the function and phenotype of genetically edited immune cells using molecular techniques (Nucleic Acid Isolation, PCR, ELISA, Western Blot, and qPCR), in vitro co-culture assays, and multiparameter flow cytometry.
  • Analyze, compile, and present results when necessary to the appropriate forums.
  • Maintain an electronic record of all experiments and resulting data.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and cardiovascular conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality and safety standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's AI-driven R&D enhances drug discovery and development efficiency.
  • The $3.5bn agreement with Prime Medicine boosts BMS's cell and gene-therapy pipeline.
  • BMS's commitment to ESG initiatives aligns with industry sustainability trends.

What critics are saying

  • Lawsuits against HRSA and HHS could lead to regulatory and financial challenges.
  • The $6.4 billion lawsuit by UMB poses potential financial liabilities for BMS.
  • The collaboration with AI Proteins may not yield viable therapeutic candidates.

What makes Bristol-Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company invests heavily in R&D to develop new drugs and therapies.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE